Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1983 1
1984 3
1985 1
1986 2
1988 2
1989 2
1990 2
1991 1
1992 2
1993 7
1994 4
1995 5
1996 3
1997 6
1998 3
1999 4
2000 3
2001 7
2002 6
2003 2
2004 8
2005 4
2006 5
2007 5
2008 3
2009 4
2010 6
2011 3
2012 7
2013 9
2014 9
2015 8
2016 12
2017 12
2018 10
2019 6
2020 9
2021 6
2022 6
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Cutaneous Chronic Lymphocytic Leukemia"
Page 1
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Sibaud V, et al. Am J Clin Dermatol. 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. Am J Clin Dermatol. 2020. PMID: 32613545 Review.
The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocytic leukemia and other B cell malignancies. The first-generation inhibitor ibrutinib works by covalent irreversible …
The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocyt …
Cutaneous manifestations of B-cell chronic lymphocytic leukemia.
Morozova EA, Olisova OY, Nikitin EA. Morozova EA, et al. Int J Hematol. 2020 Oct;112(4):459-465. doi: 10.1007/s12185-020-02978-8. Epub 2020 Sep 5. Int J Hematol. 2020. PMID: 32889697 Review.
Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative disease characterized by the accumulation of immature monoclonal B lymphocytes in blood cells, bone marrow, spleen and lymph nodes. This is the most common type of leukemia among the …
Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative disease characterized by the accumulation of imma …
Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Karsten H, Matrisch L, Cichutek S, Fiedler W, Alsdorf W, Block A. Karsten H, et al. Front Immunol. 2023 Nov 27;14:1285406. doi: 10.3389/fimmu.2023.1285406. eCollection 2023. Front Immunol. 2023. PMID: 38090582 Free PMC article. Review.
Currently, a number of CD19- or BCMA-specific CAR-T-cell therapies are approved for acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma (MM), and follicular lymphoma (FL). ...We focus on B- a …
Currently, a number of CD19- or BCMA-specific CAR-T-cell therapies are approved for acute lymphoblastic leukemia (ALL), diffuse large …
Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia: a systematic review of the literature.
Lai M, Pampena R, Cornacchia L, Odorici G, Piccerillo A, Pellacani G, Peris K, Longo C. Lai M, et al. Int J Dermatol. 2022 May;61(5):548-557. doi: 10.1111/ijd.15813. Epub 2021 Aug 5. Int J Dermatol. 2022. PMID: 34351635 Free PMC article. Review.
The continuous improvement of life expectancy of patients with chronic lymphocytic leukemia (CLL) has resulted in increased risk of second primary malignancy that potentially may affect survival and quality of life of CLL patients. We performed a systematic r …
The continuous improvement of life expectancy of patients with chronic lymphocytic leukemia (CLL) has resulted in incre …
Galectins in hematological malignancies.
Giordano M, Croci DO, Rabinovich GA. Giordano M, et al. Curr Opin Hematol. 2013 Jul;20(4):327-35. doi: 10.1097/MOH.0b013e328362370f. Curr Opin Hematol. 2013. PMID: 23695449 Review.
Increased expression of galectin-1 has been associated with tumor progression in Hodgkin's lymphoma and chronic lymphocytic leukemia, whereas galectin-3 plays a supporting role in chronic myelogenous leukemia and multiple myeloma. ...Interventio …
Increased expression of galectin-1 has been associated with tumor progression in Hodgkin's lymphoma and chronic lymphocytic …
Primary Cutaneous B-Cell Lymphomas with Large Cell Morphology: A Practical Review.
Ronchi A, Vitiello P, D'Abbronzo G, Caccavale S, Argenziano G, Sica A, Alfano R, Savarese G, Berretta M, Cozzolino I, Franco R. Ronchi A, et al. Int J Mol Sci. 2023 Mar 25;24(7):6204. doi: 10.3390/ijms24076204. Int J Mol Sci. 2023. PMID: 37047176 Free PMC article. Review.
A minority of cases consist of primary cutaneous B-cell lymphomas (PCBCLs). PCBCLs are a heterogeneous group of rare neoplasms with an overlapping morphological and immunohistochemical picture of the different subtypes. ...This work aimed to provide a practic …
A minority of cases consist of primary cutaneous B-cell lymphomas (PCBCLs). PCBCLs are a heterogeneous group of rare ne …
Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL).
Aldapt MB, Yassin M. Aldapt MB, et al. Acta Biomed. 2021 May 12;92(2):e2021192. doi: 10.23750/abm.v92i2.10763. Acta Biomed. 2021. PMID: 33988158 Free PMC article. Review.
BACKGROUND AND OBJECTIVE: Cutaneous infiltration by Chronic Lymphocytic Leukemia (CLL) is a rare complication. ...Skin infiltration by CLL does not affect prognosis, as most patients attained complete or partial remission with a very low progres …
BACKGROUND AND OBJECTIVE: Cutaneous infiltration by Chronic Lymphocytic Leukemia (CLL) is a rare complication. . …
Morphologic Diversity of Merkel Cell Carcinoma.
Ogawa T, Donizy P, Wu CL, Cornejo KM, Ryś J, Hoang MP. Ogawa T, et al. Am J Dermatopathol. 2020 Sep;42(9):629-640. doi: 10.1097/DAD.0000000000001548. Am J Dermatopathol. 2020. PMID: 32833736 Review.
Merkel cell carcinoma (MCC) is a rare and highly aggressive neuroendocrine carcinoma of unknown origin. We performed a retrospective histologic review of primary cutaneous MCCs diagnosed from 1997 to 2018 in several clinical institutions and literature review to determine …
Merkel cell carcinoma (MCC) is a rare and highly aggressive neuroendocrine carcinoma of unknown origin. We performed a retrospective histolo …
SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?
Gordiienko I, Shlapatska L, Kovalevska L, Sidorenko SP. Gordiienko I, et al. Clin Immunol. 2019 Jul;204:14-22. doi: 10.1016/j.clim.2018.10.015. Epub 2018 Oct 25. Clin Immunol. 2019. PMID: 30616923 Review.
In hematologic malignancies CD150 cell surface expression is restricted to cutaneous T-cell lymphomas, few types of B-cell non-Hodgkin's lymphoma, near half of cases of chronic lymphocytic leukemia, Hodgkin's lymphoma, and multiple myelom …
In hematologic malignancies CD150 cell surface expression is restricted to cutaneous T-cell lymphomas, few types of B-cell …
Skin lesions in chronic lymphocytic leukemia.
Robak E, Robak T. Robak E, et al. Leuk Lymphoma. 2007 May;48(5):855-65. doi: 10.1080/10428190601137336. Leuk Lymphoma. 2007. PMID: 17487727 Review.
Cutaneous lesions occur in up to 25% of patients with chronic lymphocytic leukemia (CLL). These can be caused by either cutaneous seeding by leukemic cells (leukemia cutis, LC) and other malignant diseases or nonmalignant disorders. ...
Cutaneous lesions occur in up to 25% of patients with chronic lymphocytic leukemia (CLL). These can be caused by …
182 results